局所ドラッグデリバリーの世界市場予測(〜2025):種類別(半固形物(クリーム、軟膏、ジェル、ローション、液体、固形物、経皮吸収剤))、経路別(皮膚、直腸、膣)、患者ケア設定別(ホームケア、病院、火傷治療センター)、新型コロナウイルス感染症の影響

◆英語タイトル:Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions, Liquids, Solids, Transdermal Products), Route (Dermal, Rectal, Vaginal), Patient Care Setting (Homecare, Hospital, Burn Center) COVID-19 Impact - Global Forecast to 2025
◆商品コード:PH 7545
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年9月29日
◆ページ数:264
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Marketsandmarkets社は局所ドラッグデリバリーの世界市場が2020年952億ドルから2025年1298億ドルまで、年平均6.4%成長すると展望しています。本調査レポートでは、局所ドラッグデリバリーの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(半固体製剤、液体製剤、固体製剤、経皮製品)分析、投与経路別(皮膚ドラッグデリバリー、眼科ドラッグデリバリー、直腸ドラッグデリバリー、膣ドラッグデリバリー、鼻ドラッグデリバリー)分析、使用施設別(在宅ケア設定、病院・診療所、火傷治療センター)分析、地域別分析、競争状況、企業情報など、以下の構成でお届けいたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・局所ドラッグデリバリーの世界市場規模:製品別(半固体製剤、液体製剤、固体製剤、経皮製品)
・局所ドラッグデリバリーの世界市場規模:投与経路別(皮膚ドラッグデリバリー、眼科ドラッグデリバリー、直腸ドラッグデリバリー、膣ドラッグデリバリー、鼻ドラッグデリバリー)
・局所ドラッグデリバリーの世界市場規模:使用施設別(在宅ケア設定、病院・診療所、火傷治療センター)
・局所ドラッグデリバリーの世界市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period.” The growth of this market is majorly driven by the high prevalence of skin and soft tissue infections, the increasing prevalence of eye diseases, and burns. However, the presence of alternative drug delivery modes such as oral and injectable routes is expected to restrain the growth of this market during the forecast period.

“Based on product, the semi-solid formulations segment holds the largest market share during the forecast period.”
Based on product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. The semi-solid formulations segment accounted for the larger market share in 2019. The easy application of semi-solid formulations, and their ability to deliver a wide variety of drug molecules is resulting in a stable demand for this segment among end users.

“Based on route of administration, the dermal drug delivery segment is expected to register the highest CAGR during the forecast period.”
Based on route of administration, the topical drug delivery market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal, vaginal drug delivery, and nasal drug delivery. The dermal drug delivery segment is expected to witness the highest growth during the forecast period. This is mainly due to the advantages of dermal drug delivery over other topical drug delivery methods, such as convenience and greater patient compliance. Besides, dermal products have fewer regulatory requirements than ophthalmic products, where sterility testing is mandatory.

“The home care settings segment is expected to account for the largest share of the topical drug delivery market in 2019”
The home care settings segment accounted for the largest share of the market in 2019. This is attributed to the factors such as the convenience and affordability of topical drugs for home administration. Also, for patients requiring long-term therapy, inpatient care is not only extremely expensive but also prevents patients from resuming a normal lifestyle and work activities. In this regard, technological advancements have helped patients undergo therapies effectively and safely at home.

“Asia Pacific is expected to grow at the highest CAGR in the topical drug delivery market during the forecast period”
The topical drug delivery market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. This is due to high incidence of skin diseases (such as skin cancer), increasing use of contraceptives, and the growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, all of which are driving adoption of topical drug delivery in the Asia Pacific.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–55%, Tier 2–25% and Tier 3–20%
• By Designation – C-level–43%, Director-level–32%, Others–25%
• By Region – North America–38%, Europe–29%, Asia Pacific–23%, RoW- 10%

Key players in the topical drug delivery market
The key players operating in the topical drug delivery market include Johnson & Johnson (US), Nestlé SA (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bausch Health Companies (Canada), Merck & Co (US), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Glenmark Pharmaceuticals (India), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), Mylan (US), Encore Dermatology, Inc. (US), LEO Pharma (Denmark), Almirall, S.A (Spain), Aclaris Therapeutics, Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teligent Pharma (US), Perrigo Pharma (US), Allergan (Ireland), Biofrontera, Inc. (US), Crown Laboratories Inc. (US), Akorn Inc. (US), Ingenus Pharmaceuticals (US), and Sun Pharmaceuticals (India).

Research Coverage:
The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as product, route of administration, facility of use, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global topical drug delivery market. The report analyzes this market by product, route of administration, and facility of use
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global topical drug delivery market
• Market Development: Comprehensive information on the lucrative emerging markets by product, route of administration, and facility of use
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global topical drug delivery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global topical drug delivery market.

【レポートの目次】

1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.2.1 INCLUSIONS AND EXCLUSIONS 37
1.2.2 MARKETS COVERED 38
FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION 38
1.2.3 YEARS CONSIDERED FOR THE STUDY 38
1.3 CURRENCY 39
1.4 LIMITATIONS 39
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH METHODOLOGY 41
FIGURE 3 RESEARCH DESIGN 42
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 44
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 44
2.1.2.1 Key data from primary sources 45
2.1.2.2 Key industry insights 45
2.2 MARKET SIZING & VALIDATION APPROACH 46
FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 46
FIGURE 6 TOP-DOWN APPROACH 47
2.3 MARKET DATA VALIDATION AND TRIANGULATION 49
FIGURE 7 DATA TRIANGULATION METHODOLOGY 49
2.4 MARKET SHARE ANALYSIS 49
2.5 ASSUMPTIONS FOR THE STUDY 50
3 EXECUTIVE SUMMARY 51
FIGURE 8 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020 VS 2025 (USD MILLION) 51
FIGURE 9 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2020 VS 2025 (USD MILLION) 52
FIGURE 10 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020 VS 2025 (USD MILLION) 52
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE TOPICAL DRUG DELIVERY MARKET 53
4 PREMIUM INSIGHTS 54
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW 54
FIGURE 12 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE THE GROWTH OF THE TOPICAL DRUG DELIVERY MARKET 54
4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY, 2019 55
FIGURE 13 SEMI-SOLID FORMULATIONS TO DOMINATE THE ASIA PACIFIC MARKET DURING THE FORECAST PERIOD 55
4.3 TOPICAL DRUG DELIVERY MARKET, BY REGION (2018-2025) 56
FIGURE 14 NORTH AMERICA WILL CONTINUE TO DOMINATE THE TOPICAL DRUG DELIVERY MARKET IN 2025 56
4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 57
FIGURE 15 CHINA TO SHOW THE HIGHEST REVENUE GROWTH DURING THE
FORECAST PERIOD 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
FIGURE 16 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 58
5.2.1 DRIVERS 59
5.2.1.1 High prevalence of skin diseases 59
5.2.1.2 Rising prevalence of eye diseases 59
5.2.1.3 High incidence of burn injuries 59
5.2.1.4 Growing prevalence of diabetes 59
5.2.2 RESTRAINTS 60
5.2.2.1 Preference for alternative modes of drug delivery 60
5.2.3 OPPORTUNITIES 60
5.2.3.1 Delivery of biologics through the transdermal route 60
5.2.3.2 Self-administration and home care 60
5.2.4 CHALLENGES 61
5.2.4.1 Technical barriers related to skin irritation and permeability 61
5.2.4.2 Drug failures and product recalls 61
5.3 COVID-19 IMPACT ON THE TOPICAL DRUG DELIVERY MARKET 62
FIGURE 17 IMPACT OF COVID-19 ON THE TOPICAL DRUG DELIVERY MARKET 63
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 64
6.1 INTRODUCTION 65
6.2 COVID-19 IMPACT, BY PRODUCT 65
FIGURE 18 SEMI-SOLID FORMULATIONS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019 66
TABLE 1 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 66
TABLE 2 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 67
6.3 SEMI-SOLID FORMULATIONS 67
TABLE 3 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 67
TABLE 4 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 68
TABLE 5 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY COUNTRY, 2017–2019 (USD MILLION) 68
TABLE 6 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY COUNTRY, 2020–2025 (USD MILLION) 69
6.3.1 CREAMS 69
6.3.1.1 Ease of spreadability and washability to drive this market segment 69
TABLE 7 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY,
2017–2019 (USD MILLION) 70
TABLE 8 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY,
2020–2025 (USD MILLION) 70
6.3.2 OINTMENTS 71
6.3.2.1 Ointments are widely used in analgesic indications 71
TABLE 9 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY,
2017–2019 (USD MILLION) 71
TABLE 10 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY,
2020–2025 (USD MILLION) 72
6.3.3 LOTIONS 72
6.3.3.1 Easy administration of lotions to drive their demand among end users 72
TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY,
2017–2019 (USD MILLION) 73
TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY,
2020–2025 (USD MILLION) 73
6.3.4 GELS 74
6.3.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels 74
TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY,
2017–2019 (USD MILLION) 74
TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY,
2020–2025 (USD MILLION) 75
6.3.5 PASTES 75
6.3.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation 75
TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY,
2017–2019 (USD MILLION) 76
TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY,
2020–2025 (USD MILLION) 76
6.4 LIQUID FORMULATIONS 77
TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 77
TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 77
TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY COUNTRY, 2017–2019 (USD MILLION) 78
TABLE 20 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY COUNTRY, 2020–2025 (USD MILLION) 78
6.4.1 SUSPENSIONS 79
6.4.1.1 Higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market 79
TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY,
2017–2019 (USD MILLION) 79
TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY,
2020–2025 (USD MILLION) 80
6.4.2 SOLUTIONS 80
6.4.2.1 Topical solutions comprise soluble chemicals that are dissolved in various solvents 80
TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY,
2017–2019 (USD MILLION) 81
TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY,
2020–2025 (USD MILLION) 81
6.5 SOLID FORMULATIONS 82
TABLE 25 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 82
TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 82
TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2017–2019 (USD MILLION) 83
TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2020–2025 (USD MILLION) 83
6.5.1 POWDERS 84
6.5.1.1 Powders have a very fine particle size that covers a large surface area per unit weight 84
TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY,
2017–2019 (USD MILLION) 84
TABLE 30 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY,
2020–2025 (USD MILLION) 85
6.5.2 SUPPOSITORIES 85
6.5.2.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug 85
TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2017–2019 (USD MILLION) 86
TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2020–2025 (USD MILLION) 86
6.6 TRANSDERMAL PRODUCTS 87
TABLE 33 COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMI-SOLID FORMULATIONS 87
TABLE 34 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017–2019 (USD MILLION) 88
TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2025 (USD MILLION) 88
TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY COUNTRY, 2017–2019 (USD MILLION) 89
TABLE 37 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY COUNTRY, 2020–2025 (USD MILLION) 89
6.6.1 TRANSDERMAL PATCHES 90
6.6.1.1 Transdermal patches accounted for the largest share of the transdermal drug delivery market in 2019 90
TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY COUNTRY, 2017–2019 (USD MILLION) 92
TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY COUNTRY, 2020–2025 (USD MILLION) 92
6.6.2 TRANSDERMAL SEMI-SOLIDS 93
6.6.2.1 Transdermal semi-solids segment to witness negative growth during the forecast period 93
TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS,
BY COUNTRY, 2017–2019 (USD MILLION) 94
TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS,
BY COUNTRY, 2020–2025 (USD MILLION) 95
7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION 96
7.1 INTRODUCTION 97
7.2 COVID-19 IMPACT, BY ROUTE OF ADMINISTRATION 97
FIGURE 19 DERMAL DRUG DELIVERY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 97
TABLE 42 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2017–2019 (USD MILLION) 98
TABLE 43 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION,
2020–2025 (USD MILLION) 98
7.3 DERMAL DRUG DELIVERY 98
7.3.1 DERMAL DRUG DELIVERY IS THE LARGEST SEGMENT IN THIS MARKET 98
TABLE 44 DERMAL DRUG DELIVERY MARKET, BY COUNTRY,
2017–2019 (USD MILLION) 99
TABLE 45 DERMAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2025 (USD MILLION) 99
7.4 OPHTHALMIC DRUG DELIVERY 100
7.4.1 INCREASING USE OF MOBILE DEVICES IS LIKELY TO IMPACT VISION, WHICH IS A KEY FACTOR SUPPORTING MARKET GROWTH 100
TABLE 46 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY,
2017–2019 (USD MILLION) 100
TABLE 47 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY,
2020–2025 (USD MILLION) 101
7.5 RECTAL DRUG DELIVERY 101
7.5.1 POOR ABSORPTION OF DRUGS THROUGH THE RECTAL
ROUTE—A KEY DISADVANTAGE ASSOCIATED WITH THIS MARKET SEGMENT 101
TABLE 48 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION) 102
TABLE 49 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION) 102
7.6 VAGINAL DRUG DELIVERY 103
7.6.1 SCOPE OF SELF-ADMINISTRATION AND EASE OF MANUFACTURING TO BOOST THE GROWTH OF THE VAGINAL DRUG DELIVERY MARKET SEGMENT 103
TABLE 50 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY,
2017–2019 (USD MILLION) 103
TABLE 51 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2025 (USD MILLION) 104
7.7 NASAL DRUG DELIVERY 104
7.7.1 HIGH EFFICACY OF NASALLY ADMINISTERED DRUGS AND GROWING PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH 104
TABLE 52 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION) 105
TABLE 53 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION) 105
8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE 106
8.1 INTRODUCTION 107
FIGURE 20 HOME CARE SETTINGS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019 107
TABLE 54 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 107
TABLE 55 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 108
8.2 HOME CARE SETTINGS 108
8.2.1 HOME CARE SETTINGS ACCOUNTED FOR THE LARGEST SHARE IN 2019 108
TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2017–2019 (USD MILLION) 109
TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2020–2025 (USD MILLION) 109
8.3 HOSPITALS AND CLINICS 110
8.3.1 RISING INCIDENCE OF SURGICAL-SITE INFECTIONS TO DRIVE MARKET GROWTH 110
TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017–2019 (USD MILLION) 110
TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2025 (USD MILLION) 111
8.4 BURN CENTERS 111
8.4.1 HIGH INCIDENCE OF BURN INJURIES ACROSS THE GLOBE TO SUPPORT THE MARKET GROWTH 111
TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY,
2017–2019 (USD MILLION) 112
TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY,
2020–2025 (USD MILLION) 112
8.5 OTHER FACILITIES 113
TABLE 62 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2017–2019 (USD MILLION) 113
TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2020–2025 (USD MILLION) 114

9 TOPICAL DRUG DELIVERY MARKET, BY REGION 115
9.1 INTRODUCTION 116
9.2 COVID-19 IMPACT, BY REGION 116
FIGURE 21 CHINA TO WITNESS THE HIGHEST GROWTH IN THE TOPICAL DRUG DELIVERY MARKET 117
TABLE 64 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017–2019 (USD MILLION) 117
TABLE 65 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2020–2025 (USD MILLION) 118
9.3 NORTH AMERICA 119
FIGURE 22 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 119
TABLE 66 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2017–2019 (USD MILLION) 120
TABLE 67 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2025 (USD MILLION) 120
TABLE 68 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 120
TABLE 69 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 121
TABLE 70 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 121
TABLE 71 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 122
TABLE 72 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 122
TABLE 73 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 122
TABLE 74 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 123
TABLE 75 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 123
TABLE 76 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 123
TABLE 77 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 124
TABLE 78 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 124
TABLE 79 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 125
TABLE 80 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION) 125
TABLE 81 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION) 126
9.3.1 US 126
9.3.1.1 Rising prevalence of skin diseases and the approval and launch of innovative topical formulations—key factors driving market growth 126
TABLE 82 PRODUCT APPROVALS & LAUNCHES IN THE US MARKET (2017–2019) 127
TABLE 83 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 128
TABLE 84 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 128
TABLE 85 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 128
TABLE 86 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 129
TABLE 87 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 129
TABLE 88 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 129
TABLE 89 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 130
TABLE 90 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 130
TABLE 91 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017–2019 (USD MILLION) 130
TABLE 92 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2025 (USD MILLION) 131
TABLE 93 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 131
TABLE 94 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 131
TABLE 95 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 132
TABLE 96 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 132
9.3.2 CANADA 132
9.3.2.1 Rising prevalence of skin diseases and funding for the development of topical drugs to drive market growth 132
TABLE 97 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 133
TABLE 98 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 133
TABLE 99 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 134
TABLE 100 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 134
TABLE 101 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 135
TABLE 102 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 135
TABLE 103 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 135
TABLE 104 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 136
TABLE 105 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 136
TABLE 106 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 136
TABLE 107 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 137
TABLE 108 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 137
TABLE 109 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 138
TABLE 110 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 138
9.4 EUROPE 139
TABLE 111 RECENT DEVELOPMENTS IN THE EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2015–2018 139
FIGURE 23 EUROPE: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 140
TABLE 112 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2017–2019 (USD MILLION) 141
TABLE 113 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2025 (USD MILLION) 141
TABLE 114 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 142
TABLE 115 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 142
TABLE 116 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 143
TABLE 117 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 143
TABLE 118 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 144
TABLE 119 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 144
TABLE 120 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 144
TABLE 121 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 145
TABLE 122 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 145
TABLE 123 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 145
TABLE 124 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 146
TABLE 125 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 146
TABLE 126 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 147
TABLE 127 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 147
9.4.1 GERMANY 147
9.4.1.1 Growing focus of pharmaceutical companies on the development of topical products to drive market growth 147
TABLE 128 DEVELOPMENTS IN THE FIELD OF TOPICAL DRUG DELIVERY IN GERMANY, 2017–2019 148
TABLE 129 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 149
TABLE 130 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 149
TABLE 131 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 150
TABLE 132 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 150
TABLE 133 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 151
TABLE 134 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 151
TABLE 135 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 151
TABLE 136 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 152
TABLE 137 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 152
TABLE 138 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 152
TABLE 139 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 153
TABLE 140 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 153
TABLE 141 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 154
TABLE 142 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 154

9.4.2 UK 154
9.4.2.1 Rising prevalence of skin diseases & chronic conditions to drive market growth 154
TABLE 143 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE UK,
2016–2019 155
TABLE 144 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 156
TABLE 145 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 156
TABLE 146 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 156
TABLE 147 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 157
TABLE 148 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 157
TABLE 149 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 157
TABLE 150 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 158
TABLE 151 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 158
TABLE 152 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017–2019 (USD MILLION) 158
TABLE 153 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2025 (USD MILLION) 159
TABLE 154 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 159
TABLE 155 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 160
TABLE 156 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 160
TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 160
9.4.3 FRANCE 161
9.4.3.1 Rising prevalence of skin diseases and development of topical drugs by local players to support market growth 161
TABLE 158 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 161
TABLE 159 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 162
TABLE 160 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 162
TABLE 161 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 163
TABLE 162 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 163
TABLE 163 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 163
TABLE 164 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 164
TABLE 165 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 164
TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 164
TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 165
TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 165
TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 166
TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 166
TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 167
9.4.4 REST OF EUROPE 167
TABLE 172 ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 168
TABLE 173 ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 168
TABLE 174 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 169
TABLE 175 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 169
TABLE 176 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 170
TABLE 177 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 170
TABLE 178 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 170
TABLE 179 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 171
TABLE 180 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017–2019 (USD MILLION) 171
TABLE 181 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2025 (USD MILLION) 171
TABLE 182 ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 172
TABLE 183 ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 172
TABLE 184 ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 173
TABLE 185 ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 173
9.5 ASIA PACIFIC 174
TABLE 186 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE
ASIA PACIFIC, 2016–2019 174
FIGURE 24 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 176
TABLE 187 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2017–2019 (USD MILLION) 177
TABLE 188 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2020–2025 (USD MILLION) 177
TABLE 189 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 178
TABLE 190 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 178
TABLE 191 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 179
TABLE 192 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 179
TABLE 193 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 180
TABLE 194 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 180
TABLE 195 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 180
TABLE 196 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 181
TABLE 197 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 181
TABLE 198 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 181
TABLE 199 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 182
TABLE 200 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 182
TABLE 201 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION) 183
TABLE 202 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION) 183
9.5.1 JAPAN 183
9.5.1.1 Increasing number of product approvals and growing focus of local players on the R&D of topical formulations to support market growth 183
TABLE 203 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 185
TABLE 204 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 185
TABLE 205 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 186
TABLE 206 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 186
TABLE 207 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 187
TABLE 208 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 187
TABLE 209 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 187
TABLE 210 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 188
TABLE 211 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 188
TABLE 212 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 188
TABLE 213 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 189
TABLE 214 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 189
TABLE 215 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 190
TABLE 216 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 190
9.5.2 CHINA 190
9.5.2.1 Growing focus of major players in China on the development of topical drugs to drive market growth 190
TABLE 217 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 191
TABLE 218 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 191
TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 192
TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 192
TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 193
TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 193
TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 193
TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 194
TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 194
TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 194
TABLE 227 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 195
TABLE 228 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 195
TABLE 229 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 196
TABLE 230 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 196
9.5.3 INDIA 196
9.5.3.1 Rising awareness among healthcare providers & patients and increasing focus on noninvasive methods of drug delivery to drive market growth 196
TABLE 231 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 197
TABLE 232 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 198
TABLE 233 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 198
TABLE 234 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 199
TABLE 235 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 199
TABLE 236 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 199
TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 200
TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 200
TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017–2019 (USD MILLION) 200
TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2025 (USD MILLION) 201
TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 201
TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 202
TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 202
TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 203
9.5.4 REST OF ASIA PACIFIC 203
TABLE 245 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 204
TABLE 246 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 204
TABLE 247 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 205
TABLE 248 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 205
TABLE 249 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 206
TABLE 250 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 206
TABLE 251 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 206
TABLE 252 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 207
TABLE 253 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION) 207
TABLE 254 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION) 207
TABLE 255 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 208
TABLE 256 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 208
TABLE 257 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 209
TABLE 258 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 209
9.6 REST OF THE WORLD 210
FIGURE 25 REST OF THE WORLD: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 210
TABLE 259 ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2017–2019 (USD MILLION) 211
TABLE 260 ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2020–2025 (USD MILLION) 211
TABLE 261 ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION) 211
TABLE 262 ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION) 212
TABLE 263 ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 212
TABLE 264 ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 212
TABLE 265 ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2017–2019 (USD MILLION) 213
TABLE 266 ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2020–2025 (USD MILLION) 213
TABLE 267 ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2017–2019 (USD MILLION) 213
TABLE 268 ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2020–2025 (USD MILLION) 214
TABLE 269 ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 214
TABLE 270 ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION) 215
TABLE 271 ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2017–2019 (USD MILLION) 215
TABLE 272 ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,
2020–2025 (USD MILLION) 216
10 COMPETITIVE LANDSCAPE 217
10.1 OVERVIEW 217
10.2 MARKET SHARE ANALYSIS 217
FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYERS (2019) 217
10.3 COMPETITIVE SCENARIO 218
10.3.1 PRODUCT LAUNCHES 218
TABLE 273 PRODUCT LAUNCHES 218
10.3.2 EXPANSIONS 219
TABLE 274 EXPANSIONS 219
10.3.3 AGREEMENTS AND COLLABORATIONS 219
TABLE 275 AGREEMENTS AND COLLABORATIONS 219
10.3.4 ACQUISITIONS 220
TABLE 276 ACQUISITIONS 220
10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019) 220
10.4.1 STAR PLAYERS 220
10.4.2 EMERGING LEADERS 221
10.4.3 PERVASIVES 221
10.4.4 EMERGING COMPANIES 221
FIGURE 27 TOPICAL DRUG DELIVERY MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019 221

11 COMPANY PROFILES 222
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1 BAUSCH HEALTH COMPANIES 222
FIGURE 28 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT (2019) 222
11.2 HISAMITSU PHARMACEUTICAL 225
FIGURE 29 HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT (2019) 225
11.3 NESTLÉ SA 228
FIGURE 30 NESTLÉ SA: COMPANY SNAPSHOT (2019) 228
11.4 GLENMARK PHARMACEUTICALS 231
FIGURE 31 GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT (2019) 231
11.5 CIPLA 234
FIGURE 32 CIPLA: COMPANY SNAPSHOT (2020) 234
11.6 CRESCITA THERAPEUTICS INC. 238
FIGURE 33 CRESCITA THERAPEUTICS: COMPANY SNAPSHOT (2019) 238
11.7 MYLAN N.V. 241
FIGURE 34 MYLAN: COMPANY SNAPSHOT (2019) 241
11.8 GLAXOSMITHKLINE 243
FIGURE 35 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019) 243
11.9 JANSSEN GLOBAL SERVICES (A SUBSIDIARY OF JOHNSON & JOHNSON) 246
FIGURE 36 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019) 246
11.10 3M 250
FIGURE 37 3M: COMPANY SNAPSHOT (2019) 250
11.11 MERCK & CO. 252
FIGURE 38 MERCK & CO.: COMPANY SNAPSHOT (2019) 252
11.12 BAYER AG 254
FIGURE 39 BAYER AG: COMPANY SNAPSHOT (2019) 254
11.13 NOVARTIS AG 256
FIGURE 40 NOVARTIS AG: COMPANY SNAPSHOT (2019) 256
11.14 BOEHRINGER INGELHEIM 260
FIGURE 41 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019) 260
11.15 PFIZER, INC. 262
FIGURE 42 PFIZER, INC.: COMPANY SNAPSHOT (2019) 262
11.16 OTHER MAJOR COMPANIES 264
11.16.1 TEVA PHARMACEUTICALS 264
11.16.2 BRISTOL-MYERS SQUIBB 265
11.16.3 LEAD CHEMICALS CO., INC. 265
11.16.4 LAVIPHARM 266
11.16.5 PURDUE PHARMA L.P. 267
*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

12 APPENDIX 268
12.1 DISCUSSION GUIDE 268
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 272
12.3 RELATED REPORTS 274
12.4 AUTHOR DETAILS 275

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[局所ドラッグデリバリーの世界市場予測(〜2025):種類別(半固形物(クリーム、軟膏、ジェル、ローション、液体、固形物、経皮吸収剤))、経路別(皮膚、直腸、膣)、患者ケア設定別(ホームケア、病院、火傷治療センター)、新型コロナウイルス感染症の影響]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆